Row over Mylan EpiPen boils down to plastic cap
Firm urges FDA to approve Teva's generic devices only if they were truly equivalent and wouldn't confuse patients
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Washington
THE lack of a cheaper version of Mylan NV's EpiPen shot may come down to a dispute between drugmakers over a plastic cap.
Unlike Mylan's one-cap EpiPen, Teva Pharmaceutical Industries' proposed substitutable generic version has two caps, including a removable one that covers the spot where its needle extends. In a petition to the US Food and Drug Administration (FDA), Mylan cited that difference as the key reason the agency should reject Teva's generic - which is exactly what happened in February of this year.
Share with us your feedback on BT's products and services
TRENDING NOW
‘We’ve seen the worst-case scenario’: How Indonesia’s Cinema XXI navigated crisis and change
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
S-E Asia tourism takes hit from Middle East crisis, but intra-regional travel could spell hope
Auditors flag uncertainty on Katrina Group’s ability to continue as a going concern
